A Clinical Efficacy and Safety Study of SHP607 in Preventing Chronic Lung Disease in Extremely Premature Infants

  • End date
    Feb 28, 2025
  • participants needed
  • sponsor
Updated on 21 July 2021
investigational drug
pulmonary disease
premature birth
chronic lung disease


The purpose of this study is to determine if an investigational drug can reduce the burden of chronic lung disease in extremely premature babies through 12 months corrected age (CA), as compared to extremely premature babies receiving standard neonatal care alone.

Condition Bronchopulmonary Dysplasia, Retinopathy of Prematurity, Intraventricular Hemorrhage, Intraventricular Haemorrhage, bronchopulmonary dysplasia (bpd)
Treatment SHP607
Clinical Study IdentifierNCT03253263
Last Modified on21 July 2021

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note